Metfoam 850 Tablet contains Metformin 850 mg, a first-line oral antidiabetic agent widely used for the management of type 2 diabetes mellitus. Metformin works primarily by reducing hepatic glucose production and improving insulin sensitivity, helping maintain stable blood sugar levels throughout the day.
It is a cornerstone therapy for diabetes management and is often prescribed alone or in combination with other antidiabetic medications to achieve optimal glycemic control. Metformin 850 mg is effective in controlling fasting and postprandial glucose levels, making it essential for long-term metabolic regulation.
Belonging to the antidiabetic and endocrinology segment, Metfoam 850 Tablet is highly trusted by healthcare professionals for its efficacy, tolerability, and safety profile. It has widespread demand across hospitals, clinics, and pharmacies.
For PCD pharma franchise partners, third-party manufacturers, and exporters, Metfoam 850 Tablet offers a reliable business opportunity. With the increasing prevalence of type 2 diabetes, it ensures strong market demand and consistent revenue potential in the B2B pharma sector.